Bayesian Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bayesian Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,931	Closed	-$1.23M	–	1123
2024 Q1	$1.23M	Buy	+2,931	New	+$1.24M	0.12%	245
2023 Q2	–	Sell	-9,131	Closed	-$2.88M	–	1082
2023 Q1	$2.88M	Buy	+9,131	New	+$2.74M	0.36%	74
2022 Q3	–	Sell	-1,831	Closed	-$516K	–	1039
2022 Q2	$516K	Sell	1,831 -7,869	-81%	-$2.11M	0.1%	327
2022 Q1	$2.53M	Buy	9,700 +6,560	+209%	+$1.56M	0.38%	41
2021 Q4	$690K	Buy	+3,140	New	+$611K	0.22%	136
2021 Q1	–	Sell	-6,100	Closed	-$1.44M	–	704
2020 Q4	$1.44M	Sell	6,100 -5,222	-46%	-$1.2M	0.38%	66
2020 Q3	$3.08M	Buy	+11,322	New	+$3.12M	0.75%	17
2020 Q1	–	Sell	-5,800	Closed	-$1.27M	–	997
2019 Q4	$1.27M	Buy	5,800 +4,308	+289%	+$872K	0.22%	139
2019 Q3	$253K	Buy	+1,492	New	+$264K	0.05%	402
2018 Q3	–	Sell	-16,421	Closed	-$2.79M	–	812
2018 Q2	$2.79M	Buy	16,421 +13,839	+536%	+$2.15M	0.63%	24
2018 Q1	$421K	Buy	+2,582	New	+$422K	0.11%	307
2017 Q1	–	Sell	-9,253	Closed	-$682K	–	708
2016 Q4	$682K	Buy	+9,253	New	+$753K	0.17%	230

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bayesian Capital Management's VRTX Position: Q2 2024 in Review

Bayesian Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 2,931 shares — an estimated $1.23M sold.

Bayesian Capital Management first reported a position in VRTX in Q4 2016 and held it in 12 quarters. The position peaked at $3.08M in Q3 2020. 1,549 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Bayesian Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Bayesian Capital Management sold 2,931 Vertex Pharmaceuticals shares in Q2 2024, an estimated $1.23M.
Bayesian Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 12 quarters.
Bayesian Capital Management's Vertex Pharmaceuticals position peaked at $3.08M in Q3 2020.
1,549 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.